Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs. 

Here is a video presented by Maxime DUMONT our Global Product Manager to brief you on this product .


Other sources

Check our FAQs

These FAQs are organized by application to guide you to find the best answer possible.

Product Documents

You have access to all the documents related to the Polyplus Products such as MSDS, NHPS and Posters.

Polyplus-transfection Database

Search for publications in the Transfection Database with Polyplus transfection reagents or for transfection conditions. Over 6000 publications, 1000 cell lines and primary cells available.


This lexicon will help you to understand the different terms related to Polyplus products and services.